What's Happening?
Seaport Therapeutics, in collaboration with the Monash Institute of Pharmaceutical Sciences, has been awarded up to $15 million by the Advanced Research Projects Agency for Health (ARPA-H) to advance GlyphCele, an oral therapeutic designed to restore
gut lymphatic function. This therapy aims to address metabolic diseases and pancreatic cancer by targeting and normalizing dysfunction in the gut lymphatic system. The Glyph platform, which facilitates the delivery of therapy directly into the gut lymphatics, could potentially reduce inflammation, weight gain, and insulin resistance.
Why It's Important?
The development of GlyphCele represents a significant advancement in treating metabolic diseases and pancreatic cancer by addressing the root cause rather than just managing symptoms. If successful, this therapy could lead to a new class of oral medicines that target lymphatic dysfunction, offering a non-surgical solution to a problem that currently lacks effective treatments. This could pave the way for future therapies targeting other diseases driven by lymphatic dysfunction, potentially transforming patient outcomes and expanding treatment options.
